Research Topics
| Alexander Gg TurpieSummaryAffiliation: McMaster University Country: Canada Publications
| Collaborators
|
Detail Information
Publications
Venous thromboembolism prophylaxis: role of factor xa inhibition by fondaparinuxA G G Turpie
Department of Medicine, Hamilton Health Sciences, General Hospital, Hamilton, Ontario, Canada
Surg Technol Int 13:261-7. 2004..4% (p<0.001). Four-week fondaparinux could become the standard thromboprophylaxis after hip fracture surgery. Fondaparinux is the first selective factor Xa inhibitor approved for use in thromboprophylaxis after orthopedic surgery...- BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging studyA G G Turpie
HHS General Hospital, Hamilton, Canada
J Thromb Haemost 3:2479-86. 2005..BAY 59-7939, a novel, oral, direct factor Xa inhibitor, is in clinical development for the prevention of venous thromboembolism (VTE), a frequent complication following orthopaedic surgery... 
Venous and arterial thrombosis--pathogenesis and the rationale for anticoagulationAlexander G G Turpie
Department of Medicine, McMaster University, Hamilton, Ontario, Canada
Thromb Haemost 105:586-96. 2011..Based on scientific rationale, both factor Xa and thrombin are viable targets for effective anticoagulation...- Venous thromboembolism risk in ischemic stroke patients receiving extended-duration enoxaparin prophylaxis: results from the EXCLAIM studyAlexander G G Turpie
Department of Medicine, McMaster University, Hamilton Health Sciences General Hospital, 237 Barton Street East, Hamilton, Ontario L8L 2X2, Canada
Stroke 44:249-51. 2013.... - Management consensus guidance for the use of rivaroxaban - an oral, direct factor Xa inhibitorA G G Turpie
Alexander G G Turpie, MD, Department of Medicine, McMaster University, Hamilton Health Sciences General Hospital, 237 Barton Street East, Hamilton, Ontario L8L 2X2, Canada, Tel 1 416 363 6726, Fax 1 905 628 9505, E mail
Thromb Haemost 108:876-86. 2012.... 
Rationale and design of XAMOS: noninterventional study of rivaroxaban for prophylaxis of venous thromboembolism after major hip and knee surgeryAlexander G G Turpie
Department of Medicine, General Division, Hamilton Health Sciences, Ontario, Canada
Vasc Health Risk Manag 8:363-70. 2012..XAMOS was started in 2009 and will complete recruitment and follow-up in 2011...- Role of new anticoagulants for the prevention of venous thromboembolism after major orthopaedic surgery and in hospitalised acutely ill medical patientsWalter Ageno
University of Insubria Ospedale di Circolo, Varese, Italy
Thromb Haemost 107:1027-34. 2012.... - Rivaroxaban for the prevention and treatment of venous thromboembolismAlexander G G Turpie
McMaster University, 237 Barton Street East, Hamilton, Ontario, Canada
Fundam Clin Pharmacol 26:33-8. 2012..With encouraging data already emerging, the promise of a simplified single-drug approach for VTE treatment is on the horizon... - Prevention of venous thromboembolism in medically ill patients: a clinical updateAlexander G G Turpie
Department of Medicine, Hamilton General Hospital, HHS McMaster Clinic, 237 Barton Street East, Hamilton, Ontario L8L 2X2, Canada
Postgrad Med J 82:806-9. 2006.... - Extended duration of thromboprophylaxis in acutely ill medical patients: optimizing therapy?A G G Turpie
Department of Medicine, Hamilton Health Sciences General Hospital, Hamilton, ON, Canada
J Thromb Haemost 5:5-11. 2007.... - The safety of fondaparinux for the prevention and treatment of venous thromboembolismAlexander G G Turpie
General Division, Hamilton Health Sciences Corporation, 237 Barton Street East, Hamilton, ON, L8L 2X2, Canada
Expert Opin Drug Saf 4:707-21. 2005..In conclusion, due to its superior efficacy and satisfactory safety, fondaparinux may substantially improve the prevention and treatment of venous thrombosis... - Superiority of fondaparinux over enoxaparin in preventing venous thromboembolism in major orthopedic surgery using different efficacy end pointsAlexander G G Turpie
Department of Medicine, Hamilton Health Sciences General Hospital, 237 Barton St East, Hamilton, ON, L8L 2X2, Canada
Chest 126:501-8. 2004.... - Thromboprophylaxis in medical patients: the role of low-molecular-weight heparinAlexander G G Turpie
Hamilton Health Sciences, Hamilton General Hospital, 237 Barton Street East, Hamilton, Ontario, Canada, L8L 2X2
Thromb Haemost 92:3-12. 2004..These studies provide solid evidence for the widespread use of thromboprophylaxis in medical patients... - The design of venous thromboembolism prophylaxis trials: fondaparinux is definitely more effective than enoxaparin in orthopaedic surgeryA G G Turpie
Department of Medicine, Hamilton Health Sciences General Hospital, Hamilton, Ontario, Canada
Int J Clin Pract 58:483-93. 2004..Fondaparinux used according to its approved regimen provides a simple, easy-to-use, effective and safe post-operative regimen for all orthopaedic surgery patients... - Fondaparinux: a Factor Xa inhibitor for antithrombotic therapyAlexander G G Turpie
Hamilton Health Sciences General Hospital, Department of Medicine, 237 Barton Street East, Hamilton, Ontario, L8L 2X2, Canada
Expert Opin Pharmacother 5:1373-84. 2004..5 mg once-daily s.c. has been approved for the prevention of venous thromboembolism after major orthopaedic surgery. Fondaparinux use in extended prophylaxis (4 weeks) after hip fracture surgery has also been recently approved... - Burden of disease: medical and economic impact of acute coronary syndromesAlexander G G Turpie
Hamilton Health Sciences General Hospital, 237 Barton St E, Hamilton, Ontario, Canada L8L 2X2
Am J Manag Care 12:S430-4. 2006..More recently developed antithrombotic agents may have clinical and economic advantages over older therapies... 
Fondaparinux in the management of patients with ST-elevation acute myocardial infarctionAlexander G G Turpie
Hamilton Health Sciences Corporation General Division, Hamilton, ON, Canada
Vasc Health Risk Manag 2:371-8. 2006..Overall, the data from the OASIS studies showed that fondaparinux 2.5 mg may represent a new anticoagulant standard in patients with acute coronary syndromes...- Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseasesAlexander G G Turpie
HHS General Hospital, Hamilton, Canada
Arterioscler Thromb Vasc Biol 27:1238-47. 2007..It is hoped that, before long, these anticoagulants will allow us to enter an era of convenient, oral anticoagulation, without the need for regular monitoring or dose adjustment... - Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studiesAlexander G G Turpie
McMaster University, Hamilton, Ontario, Canada
Thromb Haemost 105:444-53. 2011.... - Direct Factor Xa and direct thrombin inhibitors: a clinical trial updateAlexander G G Turpie
McMaster University, Hamilton, ON, Canada
Curr Opin Drug Discov Devel 12:497-508. 2009..This review provides an update on clinical trials of the direct FXa and thrombin inhibitors... - Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trialAlexander G G Turpie
McMaster University, Hamilton, Ontario L8L 2X2, Canada
Lancet 373:1673-80. 2009..We aimed to test the efficacy and safety of oral rivaroxaban for the prevention of venous thromboembolism after total knee arthroplasty... - Pharmacokinetic and clinical data supporting the use of fondaparinux 1.5 mg once daily in the prevention of venous thromboembolism in renally impaired patientsAlexander G G Turpie
Department of Medicine, Hamilton Health Sciences, 237 Barton Street East, Hamilton, Ontario, Canada
Blood Coagul Fibrinolysis 20:114-21. 2009..5 mg in patients with normal renal function. This dosage regimen showed a favorable efficacy/safety clinical profile and should be appropriate in preventing venous thromboembolism in patients with moderate renal impairment... - The top 4 advances in antithrombotic care in the last yearAlexander G G Turpie
McMaster University, Hamilton, Canada
Thromb Res 123:S2-6. 2008..Finally, the approval of new practice-changing, paradigm-shifting oral anticoagulants is on the horizon. This article will review the top 4 advances in antithrombotic care and discuss their impact on the clinical management of VTE... - New oral anticoagulants in atrial fibrillationAlexander G G Turpie
Department of Medicine, HHS General Hospital, 237 Barton Street East, Hamilton, Ontario, Canada L8L 2X2
Eur Heart J 29:155-65. 2008..If approved, they may represent the next generation of anticoagulants, by providing new therapeutic options for stroke prevention in patients with AF... - Fondaparinux combined with intermittent pneumatic compression vs. intermittent pneumatic compression alone for prevention of venous thromboembolism after abdominal surgery: a randomized, double-blind comparisonA G G Turpie
Department of Medicine, Hamilton Health Sciences, McMaster University, Hamilton, ON, Canada
J Thromb Haemost 5:1854-61. 2007..The benefit of combined mechanical and pharmacologic methods for venous thromboembolism prevention after abdominal surgery has not been clearly established... - New pentasaccharides for the prophylaxis of venous thromboembolism: clinical studiesAlexander G G Turpie
Department of Medicine, Hamilton Health Sciences General Hospital, 237 Barton Street East, Hamilton, Ontario L8L 2X2, Canada
Chest 124:371S-378S. 2003..Fondaparinux has been recently approved for use in thromboprophylaxis after major orthopedic surgery. The clinical development of fondaparinux in other thromboprophylactic indications is ongoing... - Future therapeutic directions for factor Xa inhibition in the prophylaxis and treatment of thrombotic disordersAlexander G G Turpie
McMaster University, Hamilton Health Sciences General Hospital, Hamilton, Ontario L8L 2X2, Canada
Am J Health Syst Pharm 60:S20-4. 2003..The orthopedic prophylactic and nonorthopedic clinical programs for fondaparinux in the management of thrombosis support the concept that targeted inhibition of coagulation is an effective advance in antithrombotic therapy... - Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studiesAlexander G G Turpie
Department of Medicine, Hamilton Health Sciences General Hospital, 237 Barton, Hamilton, Ontario, Canada L8L 2X2
Arch Intern Med 162:1833-40. 2002..Fondaparinux, the first of a new class of synthetic selective factor Xa inhibitors, may further reduce this risk compared with currently available thromboprophylactic treatments... - State of the art--a journey through the world of antithrombotic therapyAlexander G G Turpie
Department of Medicine, HHS General Hospital, McMaster Clinic, Hamilton, Ontario, Canada
Semin Thromb Hemost 28:3-11. 2002..New data indicate that combination therapy with aspirin and a novel thienopyridine, clopidogrel, may further improve outcomes in this indication... - A meta-analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgeryAlexander G G Turpie
Department of Medicine, Hamilton Health Sciences General Hospital, Hamilton, Ontario, Canada
J South Orthop Assoc 11:182-8. 2002..4%. The overall incidence of clinically relevant bleeding was low and did not differ between the two groups. The benefit of fondaparinux was consistent across all types of surgery and all subgroups... - Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trialAlexander G G Turpie
Department of Medicine, General Division, Hamilton Health Sciences Corporation, Ontario, Hamilton, Canada
Lancet 359:1721-6. 2002..We aimed to see whether the pentasaccharide fondaparinux, the first drug of a new class of synthetic antithrombotic agents, could reduce this risk to a greater extent than other available treatments... - A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT)Alexander G G Turpie
McMaster University, Hamilton, Ontario, Canada
Thromb Haemost 101:68-76. 2009..Betrixaban demonstrated antithrombotic activity and appeared well tolerated in knee replacement patients at the doses studied... - Review of enoxaparin and its clinical applications in venous and arterial thromboembolismAlexander G G Turpie
Hamilton Health Sciences, Hamilton General Hospital, 237 Barton Street East, Hamilton, Ontario, Canada, L8L 2X2
Expert Opin Pharmacother 3:575-98. 2002..Adverse events with enoxaparin are infrequent; the most common events are minor bleeding complications. It should be noted that different doses or indications are approved in each country... - Fondaparinux, the first selective factor Xa inhibitorAlexander G G Turpie
Hamilton Health Sciences General Hospital, Hamilton, Ontario, Canada
Curr Opin Hematol 10:327-32. 2003..Finally, the efficacy and safety of fondaparinux in the treatment of venous thromboembolism and acute coronary syndromes appears promising... - Use of selective factor Xa inhibitors in special populationsAlexander G G Turpie
McMaster University Hamilton Health Sciences Corporation General Site, Hamilton, Ontario, Canada
Am J Orthop (Belle Mead NJ) 31:11-5. 2002..One feature of fondaparinux is that it can be administered safely and efficaciously in a wide variety of patient populations, without the need for dosage modification... - Setting a standard for venous thromboembolism prophylaxisA G Turpie
Department of Medicine, McMaster University, Hamilton, Ontario, Canada
Am J Health Syst Pharm 58:S18-23. 2001..Fondaparinux sodium, a novel antithrombotic agent, is effective for the prevention of VTE, with a favorable safety profile, in patients undergoing major orthopedic surgery... - Pentasaccharide Org31540/SR90107A clinical trials update: lessons for practiceA G Turpie
McMaster University, Hamilton, Ontario, Canada
Am Heart J 142:S9-15. 2001..However, efficacy and safety limitations of these agents have prompted a search for alternative antithrombotic drugs... - Low-molecular-weight heparins in the treatment of acute coronary syndromesA G Turpie
HHSC General Division, 237 Barton St E, Hamilton, Ontario, Canada L8L 2X2
Arch Intern Med 161:1484-90. 2001..In clinical trials comparing low-molecular-weight heparin with heparin, only enoxaparin sodium has been shown to reduce the risk of coronary events in patients with non-ST segment elevation acute coronary ischemia... - Bilateral vs. ipsilateral venography as the primary efficacy outcome measure in thromboprophylaxis clinical trials: a systematic reviewA Y Y Lee
Department of Medicine, McMaster University, Hamilton, Ontario, Canada
J Thromb Haemost 2:1752-9. 2004.... - Low molecular weight heparins in the treatment of unstable anginaW Ageno
McMaster University, Hamilton, Canada
Minerva Cardioangiol 50:643-51. 2002..Direct comparisons are now required to determine the superiority of one compound over another... - Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous ThromboembolismVictor F Tapson
Division of Pulmonary and Critical Care, Box 31175, Room 351 Bell Building, Duke University Medical Center, Durham, NC 27710, USA
Chest 132:936-45. 2007..Our aim was to characterize the clinical practices for VTE prophylaxis in acutely ill hospitalized medical patients enrolled in the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE)... - Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studiesWilliam D Fisher
McGill University Health Centre, 1650 Cedar Avenue, Montreal, Quebec, H3G 1A4, Canada
Thromb Haemost 97:931-7. 2007..Overall, rivaroxaban total daily doses of 5-20 mg had the most favorable balance of efficacy and safety, relative to enoxaparin, for the prevention of VTE after major orthopaedic surgery... - Approach to managing musculoskeletal pain: acetaminophen, cyclooxygenase-2 inhibitors, or traditional NSAIDs?Richard H Hunt
Division of Gastroenterology at McMaster University in Hamilton, Ont
Can Fam Physician 53:1177-84. 2007..To provide family physicians and pharmacists with practical, evidence- and expertise-based guidance on choosing the safest approach to using analgesics to manage patients with musculoskeletal pain... - Early recovery and functional outcome are related with causal stroke subtype: data from the tinzaparin in acute ischemic stroke trialNikola Sprigg
Institute of Neuroscience, University of Nottingham, United Kingdom
J Stroke Cerebrovasc Dis 16:180-4. 2007..Baseline severity and causal subtype are predictors of outcome in ischemic stroke. We used data from the Tinzaparin in Acute Ischemic Stroke Trial (TAIST) to further assess the relationship among stroke subtype, early recovery, and outcome... - Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgeryWolfgang Mueck
Clinical Pharmacology, Bayer HealthCare AG, Aprather Weg 18a, Wuppertal, Germany
Clin Pharmacokinet 47:203-16. 2008.... - SR123781A: a new once-daily synthetic oligosaccharide anticoagulant for thromboprophylaxis after total hip replacement surgery: the DRIVE (Dose Ranging Study in Elective Total Hip Replacement Surgery) studyMichael R Lassen
Hørsholm Hospital, Hørsholm, Denmark
J Am Coll Cardiol 51:1498-504. 2008..This study assessed the dose response of SR123781A for the prevention of venous thromboembolism (VTE) in patients undergoing total hip replacement (THR) surgery... - Thromboprophylaxis with dalteparin in medical patients: which patients benefit?Alexander T Cohen
Department of Surgery, King s College Hospital, Bessemer Road, London SE5 9PJ, UK
Vasc Med 12:123-7. 2007..Our findings, therefore, support the broad application of thromboprophylaxis in acutely ill hospitalized medical patients... - New advances in the management of acute coronary syndromes: 4. Low-molecular-weight heparinsWalter Ageno
Department of Internal Medicine, University of Insubria, Varese, Italy
CMAJ 166:919-24. 2002 - Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparisonMichael Rud Lassen
Department of Orthopaedics, University Hospital of Copenhagen Hillerød, DK 3400, Hillerød, Denmark
Lancet 359:1715-20. 2002..We aimed to assess the ability of the pentasaccharide fondaparinux, the first of a new class of synthetic antithrombotic agents, to further reduce this risk... - Optimizing prophylaxis of venous thromboembolismAlexander G G Turpie
Hamilton Health Sciences-Hamilton General Hospital, Hamilton, Ontario, Canada
Semin Thromb Hemost 28:25-32. 2002..It has been suggested that fondaparinux's superior efficacy may be related to its ability to initiate selective inhibition of factor Xa and its predictable linear pharmacokinetics... - Benefit of selective factor inhibitionAlexander G G Turpie
Hamilton Health Sciences-Hamilton General Hospital, Hamilton, Ontario, Canada
Semin Thromb Hemost 28:49-50. 2002 - Factor Xa inhibition in the prevention of venous thromboembolism and treatment of patients with venous thromboembolismKenneth A Bauer
VA Boston Healthcare System and Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
Curr Opin Pulm Med 8:398-404. 2002..Fondaparinux also appears to be a very promising candidate for the treatment of patients with existing VTE... - PentasaccharidesAlexander G G Turpie
Hamilton Health Sciences-Hamilton General Hospital, 237 Barton Street East, Hamilton, Ontario, L8L 2X2 Canada
Semin Hematol 39:158-71. 2002.... - Perioperative bridging therapy with unfractionated heparin or low-molecular-weight heparin in patients with mechanical prosthetic heart valves on long-term oral anticoagulants (from the REGIMEN Registry)Alex C Spyropoulos
Lovelace Medical Center, Albuquerque, New Mexico, USA
Am J Cardiol 102:883-9. 2008.... - Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplastyMichael R Lassen
Nordsjaellands Hospital, Hørsholm, Denmark
N Engl J Med 358:2776-86. 2008..We investigated the efficacy of rivaroxaban, an orally active direct factor Xa inhibitor, in preventing venous thrombosis after total knee arthroplasty... - ABC of antithrombotic therapy: Venous thromboembolism: treatment strategiesAlexander G G Turpie
Department of Medicine, McMaster University, Hamilton, Canada
BMJ 325:948-50. 2002 - Valvar heart disease and prosthetic heart valvesIra Goldsmith
University Department of Medicine, City Hospital, Birmingham
BMJ 325:1228-31. 2002 - Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trialNils Kucher
Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA
Arch Intern Med 165:341-5. 2005..99) and in elderly (1.1% vs 0.7%; P=.12) patients. CONCLUSION: Our findings suggest that a fixed low dose of dalteparin sodium of 5000 U/d is effective and safe in preventing VTE in obese and elderly hospitalized medical patients... - Mortality rates and risk factors for asymptomatic deep vein thrombosis in medical patientsPaul T Vaitkus
Cardiology Division, College of Medicine, University of Illinois at Chicago, 840 S Wood St, Chicago, Illinois 60612, USA
Thromb Haemost 93:76-9. 2005..In conclusion, the high mortality rate in patients with asymptomatic proximal DVT underscores its clinical relevance and supports targeting of asymptomatic proximal DVT as an appropriate endpoint in clinical trials of thromboprophylaxis... - Prevention of venous thromboembolism among hospitalized medical patientsSamuel Z Goldhaber
Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115, USA
Circulation 111:e1-3. 2005 - FondaparinuxAlexander G G Turpie
Department of Medicine, Hamilton Health Sciences-Hamilton General Hospital and McMaster University, Hamilton, Ontario, Canada
J Am Acad Orthop Surg 12:371-5. 2004 - Unstable angina and non-ST-elevation myocardial infarction: initial antithrombotic therapy and early invasive strategyChristopher P Cannon
TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass 02115, USA
Circulation 107:2640-5. 2003 - Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patientsAlain Leizorovicz
Unite de Pharmacologie Clinique, Universite Claude Bernard Lyon I, Lyon, France
Circulation 110:874-9. 2004.... - Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX studyRaza Alikhan
Academic Department of Surgery, Guy's, King's, St Thomas' School of Medicine, London, UK
Blood Coagul Fibrinolysis 14:341-6. 2003..22 (95% CI, 0.09-0.51); immobility, 0.53 (95% CI, 0.14-1.72); previous VTE, 0.49 (95% CI, 0.15-1.68); and cancer, 0.50 (95%o CI, 0.14-1.72). The beneficial effects of enoxaparin extend to a wide range of acutely ill medical patients... - Fondaparinux and prevention of venous thromboembolism after orthopaedic surgeryAlexander G G Turpie
Lancet 362:1582-3. 2003 - Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX StudyRaza Alikhan
Academic Department of Surgery, Guy's, King's, and St Thomas' School of Medicine, London, England
Arch Intern Med 164:963-8. 2004..These findings allow recognition of individuals at increased risk of VTE and will contribute to the formulation of an evidence-based risk assessment model for thromboprophylaxis in hospitalized general medical patients... - Correlation of plasma coagulation parameters with thromboprophylaxis, patient characteristics, and outcome in the MEDENOX studyLouis Desjardins
Service hématologie, CHU Laval, Ste Foy, Quebec, Canada
Arch Pathol Lab Med 128:519-26. 2004..Plasma anti-Xa and anti-IIa activities correlate with the dose of low-molecular-weight heparin, and D-dimer and thrombin-antithrombin complexes are markers of procoagulant activity... - Perioperative management of patients receiving oral anticoagulants: a systematic reviewAndrew S Dunn
Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA
Arch Intern Med 163:901-8. 2003..The safety and efficacy of various management strategies for patients receiving oral anticoagulants (OACs) who need to undergo surgery or invasive procedures are unknown... - The clinical challenge of bridging anticoagulation with low-molecular-weight heparin in patients with mechanical prosthetic heart valves: an evidence-based comparative review focusing on anticoagulation options in pregnant and nonpregnant patientsNiranjan Seshadri
Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
Am Heart J 150:27-34. 2005..Future large-scale, randomized trials are warranted... - Stroke severity, early recovery and outcome are each related with clinical classification of stroke: data from the 'Tinzaparin in Acute Ischaemic Stroke Trial' (TAIST)Nikola Sprigg
Institute of Neuroscience, University of Nottingham, Nottingham, UK
J Neurol Sci 254:54-9. 2007..We used data from the 'Tinzaparin in Acute Ischaemic Stroke Trial' (TAIST) to assess the relationship between stroke severity, early recovery, outcome and OCSP syndrome... - Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trialAlexander T Cohen
Department of Surgery, Guy s, King s, and St Thomas s School of Medicine, London SE5 9PJ
BMJ 332:325-9. 2006..To determine the efficacy and safety of the anticoagulant fondaparinux in older acute medical inpatients at moderate to high risk of venous thromboembolism... - Extended-duration thromboprophylaxis in acutely ill medical patients with recent reduced mobility: methodology for the EXCLAIM studyRussell D Hull
Thrombosis Research Unit, Foothills Hospital, University of Calgary, Room 601 South Tower, 1403 29th Street NW, Calgary, T2N 2T9, Alberta, Canada
J Thromb Thrombolysis 22:31-8. 2006.... - Clinical trials of deep vein thrombosis prophylaxis in medical patientsWalter Ageno
Department of Clinical Medicine, Ospedale di Circolo University of Insubria Varese, Italy
Clin Cornerstone 7:16-22. 2005..The results of these studies support the evidence-based recommendations for systematic use of thromboprophylaxis in this setting... - Multicenter evaluation of the use of venous thromboembolism prophylaxis in acutely ill medical patients in CanadaSusan R Kahn
Department of Medicine, McGill University, SMBD Jewish General Hospital, Canada
Thromb Res 119:145-55. 2007..Venous thromboembolism (VTE) prophylaxis in acutely ill medical patients has been shown to be safe and effective. Underutilization of this patient safety practice may result in avoidable mortality and morbidity... - Flexibility in administration of fondaparinux for prevention of symptomatic venous thromboembolism in orthopaedic surgeryClifford W Colwell
Shiley Center for Orthopaedic Research and Education at Scripps Clinic, La Jolla, California 92037-1030, USA
J Arthroplasty 21:36-45. 2006..2% and 0.7% [P = .19], and 1.4% and 2.0% [P = .31], respectively). Delaying initiation of fondaparinux prophylaxis provides an option after total joint arthroplasty with preserved efficacy and safety... - A randomized pilot study of dalteparin versus unfractionated heparin during percutaneous coronary interventionsMadhu K Natarajan
Division of Cardiology, Department of Medicine, Hamilton Health Sciences, McMaster University, Hamilton, Ontario, Canada
Am Heart J 151:175. 2006..This study examined the relative effects of dalteparin and UFH on coagulation and angiographic and clinical indices during PCI... - Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patientsAlexander T Cohen
Vascular Medicine, Department of Surgery, Guy s, King s and St Thomas School of Medicine, London, UK
Thromb Haemost 94:750-9. 2005..These medical conditions and risk factors are included in a risk-assessment model which is hoped will provide a simple means of assisting clinicians in deciding whether thromboprophylaxis should be used in an individual patient... - A new antithrombotic strategy, the selective inhibition of coagulation factors, and its importance to the orthopedic specialistKenneth A Bauer
Department of Medicine, VA Boston Healthcare System and Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
J South Orthop Assoc 11:197-202. 2002..Fondaparinux has demonstrated its efficacy compared to a widely used low-molecular-weight heparin in a number of thromboprophylaxis trials after major orthopedic surgery and is approved for use in this setting... - Perioperative bridging interruption with heparin for the patient receiving long-term anticoagulationAlex C Spyropoulos
Clinical Thrombosis Center Lovelace Medical Center Albuquerque, New Mexico 87108, USA
Curr Opin Pulm Med 11:373-9. 2005.... - The safety of antithrombotic therapy during pregnancyWalter Ageno
Department of Internal Medicine, UO Medicina I, Ospedale di Circolo, Varese, Italy
Expert Opin Drug Saf 3:113-8. 2004..Full-dose UFH is recommended in the first trimester and after week 36. The use of LMWH as an alternative to UFH is still a matter of debate, because inadequate data are available...